Barclays
BCLI

Barclays’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Barclays’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,547
Closed -$6.33K – 5076
2023
Q4 		$6.33K Buy
+1,547
New +$4.64K ﹤0.01% 5011

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Barclays's BCLI Position: Q1 2024 in Review

Barclays sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2024, closing a stake of 1,542 shares — an estimated $6.31K sold.

Barclays first reported a position in BCLI in Q2 2020 and held it in 7 quarters. The position peaked at $221K in Q3 2020. 47 funds tracked by Wall St. Rank hold BCLI as of Q1 2024.

  • Barclays reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2024 after selling out during the quarter.
  • Barclays sold 1,542 BRAINSTORM CELL THERAPUTC shares in Q1 2024, an estimated $6.31K.
  • Barclays first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2020 and held it in 7 quarters.
  • Barclays's BRAINSTORM CELL THERAPUTC position peaked at $221K in Q3 2020.
  • 47 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2024.

Based on Barclays's 13F filing for Q1 2024, filed 15 May 2024.